Jane B Trepel Selected Research

entinostat (MS 275)

11/2021	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.
10/2021	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
1/2021	A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
1/2018	Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
1/2018	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.
1/2016	The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
6/2013	Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
9/2007	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
4/2007	Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
6/2005	Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jane B Trepel Research Topics

Disease

66	Neoplasms (Cancer) 12/2021 - 01/2002
17	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 03/2003
10	Carcinoma (Carcinomatosis) 01/2022 - 03/2003
10	Breast Neoplasms (Breast Cancer) 10/2021 - 01/2002
9	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2021 - 01/2016
7	Disease Progression 01/2022 - 02/2014
5	Lung Neoplasms (Lung Cancer) 07/2021 - 03/2005
5	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 01/2015
4	Leukemia 11/2021 - 09/2002
4	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2007
4	Circulating Neoplastic Cells 01/2021 - 04/2016
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2021 - 08/2002
3	Neutropenia 12/2020 - 11/2014
3	Diarrhea 12/2020 - 11/2011
3	Triple Negative Breast Neoplasms 12/2020 - 01/2018
3	Adenocarcinoma 01/2020 - 03/2005
3	Urinary Bladder Neoplasms (Bladder Cancer) 05/2017 - 11/2015
3	Lymphoma (Lymphomas) 01/2017 - 06/2005
3	Carcinogenesis 08/2015 - 03/2003
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 09/2008
2	Thrombocytopenia (Thrombopenia) 12/2020 - 11/2014
2	Fatigue 12/2020 - 10/2005
2	Nausea 12/2020 - 11/2014
2	Glioma (Gliomas) 01/2020 - 01/2004
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2019 - 04/2013
2	Thymoma (Thymic Carcinoma) 02/2015 - 02/2014
2	Pheochromocytoma 04/2013 - 01/2013
2	Hematologic Neoplasms (Hematological Malignancy) 05/2008 - 08/2002
2	Myeloid Leukemia (Leukemia, Myelocytic) 04/2007 - 08/2002
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2021
1	Genomic Instability 12/2021
1	Smoldering Multiple Myeloma 11/2021
1	Acute Biphenotypic Leukemia (Leukemia, Mixed Cell) 11/2021
1	Multiple Myeloma 11/2021

Drug/Important Bio-Agent (IBA)

17	Histone Deacetylase InhibitorsIBA 11/2021 - 01/2004
15	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2005
13	entinostat (MS 275)IBA 11/2021 - 02/2002
13	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2015
11	PlatinumIBA 12/2021 - 01/2015
10	Pharmaceutical PreparationsIBA 12/2020 - 01/2002
8	Immune Checkpoint InhibitorsIBA 01/2022 - 11/2015
7	Phosphotransferases (Kinase)IBA 12/2020 - 05/2008
6	AntigensIBA 07/2021 - 01/2005
6	RRx-001IBA 02/2021 - 01/2016
6	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2017 - 07/2011
5	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 07/2011
5	STA 9090IBA 01/2017 - 12/2010
4	cabozantinibIBA 01/2022 - 01/2020
4	Messenger RNA (mRNA)IBA 01/2020 - 06/2004
4	belinostatIBA 01/2018 - 11/2014
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 11/2014
4	Molecular Chaperones (Chaperone, Molecular)IBA 02/2016 - 06/2013
3	EnzymesIBA 12/2021 - 12/2019
3	Aromatase InhibitorsIBA 10/2021 - 06/2013
3	exemestane (Aromasin)FDA Link 10/2021 - 06/2013
3	VaccinesIBA 07/2021 - 08/2016
3	Docetaxel (Taxotere)FDA Link 01/2021 - 04/2010
3	B7-H1 AntigenIBA 01/2021 - 11/2015
3	Prednisone (Sone)FDA LinkGeneric 01/2021 - 04/2010
3	prexasertibIBA 12/2020 - 01/2018
3	(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA 12/2020 - 08/2015
3	Peptides (Polypeptides)IBA 11/2019 - 08/2016
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 07/2015
3	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 04/2016
3	olaparibIBA 01/2019 - 01/2015
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 02/2002
3	romidepsin (FK228)FDA Link 01/2018 - 03/2005
3	AndrogensIBA 01/2017 - 10/2005
3	DepsipeptidesIBA 09/2008 - 03/2004
3	beta CateninIBA 05/2008 - 08/2002
2	NivolumabIBA 01/2022 - 11/2020
2	Lenalidomide (CC 5013)FDA Link 11/2021 - 10/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2021 - 11/2014
2	Lactic Acid (Lactate)FDA LinkGeneric 11/2020 - 01/2020
2	InterferonsIBA 01/2020 - 05/2009
2	cediranib (AZD2171)IBA 01/2019 - 01/2015
2	Protein Isoforms (Isoforms)IBA 01/2019 - 06/2013
2	durvalumabIBA 01/2019 - 12/2018
2	Oncogene Proteins (Oncogene Protein)IBA 12/2018 - 10/2012
2	TARPIBA 12/2018 - 08/2016
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2018 - 01/2018
2	Androgen Antagonists (Antiandrogens)IBA 01/2018 - 11/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 03/2005
2	EndoglinIBA 01/2017 - 10/2015
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 01/2002
2	carotuximabIBA 01/2017 - 10/2015
2	Bevacizumab (Avastin)FDA Link 10/2016 - 04/2010
2	Estrogen ReceptorsIBA 01/2016 - 06/2013
2	Tyrosine (L-Tyrosine)FDA Link 08/2015 - 05/2008
2	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2014 - 12/2004
2	tanespimycin (17AAG)IBA 01/2013 - 12/2010
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 06/2004 - 01/2002
1	cyclopropapyrroloindoleIBA 01/2022
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 12/2021
1	carfilzomibIBA 11/2021

Therapy/Procedure

26	Therapeutics 01/2022 - 03/2003
7	Immunotherapy 11/2021 - 11/2015
7	Drug Therapy (Chemotherapy) 02/2021 - 02/2015
7	Castration 01/2021 - 04/2010
2	Aftercare (After-Treatment) 01/2020 - 12/2018